Terminated trials can still produce important data. Although the sponsor prematurely stopped the ANTHEM-HFrEF trial of vagal nerve stimulation for heart failure, the investigators published their ...

A recent analysis based on pivotal RCTs in HFrEF showed that, compared with ACEI or ARB and beta-blocker therapy, treating patients with HFrEF with comprehensive disease-modifying medical therapy ...

The meeting minutes from FDA confirm that the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for market clearance. PMA is the most rigorous type of device marketing ...

Please provide your email address to receive an email when new articles are posted on . Women with HFrEF had a 72% lower rate of LVAD use vs. men. Black men had a 46% lower rate of heart transplant vs ...

When the sympathetic nervous system is unregulated, it can lead to high blood pressure and elevated heart rate. The combination of sacubitril-valsartan, sold as Entresto, that is currently the only ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Nine out of 10 hospitalized patients who have heart failure with reduced ejection fraction (HFrEF) may be potential candidates for the novel agent vericiguat (Merck Sharp & Dohme/Bayer) to lower their ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The FDA has approved empagliflozin (Jardiance) for adults with heart failure with reduced ejection fraction, regardless of type 2 diabetes status. The FDA has approved Boehringer Ingelheim and Eli ...

Start most patients newly diagnosed with heart failure with reduced ejection fraction on the disorder's four foundational drug regimens all at once, all on the day the diagnosis is made, Gregg C.

prescription medicine Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients. Heart failure affects ...